For tumor suppressors, wild type p53 protein was reported to inhibit the phosphorylation of STAT3, and the transcriptional activity of both STAT3 and STAT5, which could be lost through TP53 mutation.36,37 Similarly, our data showed that TP53 mutation might increase sorafenib resistance via activating STAT3. This evidence concerns the gene STAT3 and neoplasm.